logo-loader

PreveCeutical Medical shifting the dial in pain management solutions, suggests article

Last updated: 19:05 05 Feb 2018 GMT, First published: 12:32 05 Feb 2018 GMT

1517852335_biotech_517925923
Opioid-based drugs are the leading treatments for pain but can be highly addictive

PreveCeutical Medical Inc (CSE: PREV, OTCQB: PRVCF), the health sciences group,  is establishing a new paradigm in pain management solutions, says a report in NetworkNewsWire.

The company is using a novel approach in developing non-addictive analgesics by engineering peptides into efficient pain blockers, eliminating highly addictive opioids, the article says.

It comes after last week's announcement of the company's research and option agreement with the University of Queensland (UQ) and UniQuest, the university’s main commercialisation company to develop non addictive painkillers, with a targeted start date for the research of March 1.

Fourth agreement

It was the fourth agreement the pair has signed over the past 12 months.

"Whether acute or chronic, caused by disease, trauma or neural damage, current pain therapeutics primarily rely on a variety of opioid-based pharmacological therapies that have ignited a severe public health crisis," the NetworkNewsWire article states.

There is a "global quest for effective opioid free medications", it added.

"...the global market for pain management drugs exceeded $62 billion in 2016 and is estimated to surpass $88 billion by 2025," it also wrote.

Highly addictive.

"Opioid-based drugs are the leading treatments for severe and chronic pain, but they can be highly addictive. Their abuse results in thousands of overdose deaths in the United States annually."

The article says "in what may be a breakthrough approach to address the critical demand for non-additive pain medications", PreveCeutical was to engineer peptides with greatly increased stability and potency and develop non-addictive analgesics for moderate-to-severe pain.

“This is a very exciting and important program as we focus on engineering a novel class of drugs derived from our very own endogenous pain pathways, for example when pain and inflammatory insults occur," said Dr Harry Parekh, PreveCeutical’s chief research officer.

"Our preliminary work has highlighted that by using our proprietary linker technology we can enhance stability while maintaining, and in some cases enhancing the potency of lead bioactives."

The four-phase research program will be led by Dr Parekh and carried out in collaboration with pain and inflammation pharmacology experts at the University of Queensland.

PreveCeutical will own all intellectual property (IP) and UniQuest, the IP and research commercialization company of the University of Queensland, will receive payments for development milestones and sales-based royalties in accordance with the terms of the research agreement.

PreveCeutical currently has five R&D programs, including: dual gene therapy for curative and prevention therapies for diabetes and obesity; a Sol-gel platform for nose-to-brain delivery of medical compounds including cannabinoids; Nature Identical peptides for treatment of various ailments; non-addictive analgesic peptides as a replacement to highly addictive analgesics such as morphine, fentanyl and oxycodone; and a therapeutic product for treating athletes who suffer from concussions (mild traumatic brain injury).

PreveCeutical Medical making key advances with its Sol-gel program

Dr Harry Parekh, chief research officer for PreveCeutical Medical Inc (CSE: PREV, OTCQB: PRVCF), tells Proactive's Andrew Scott they've hit a number of key milestones with their Sol-gel program. He says they've now successfully optimised the conditions for extracting cannabinoids from one...

on 10/9/18